Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Scott Harris

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
The American Journal of Gastroenterology|July 9, 2020
Bimodal Release Ondansetron Improves Stool Consistency and Symptomatology in Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized, Double-Blind, TrialTerry F Plasse, Gary Barton, Evelyne Davidson, et al.
The American Journal of Gastroenterology|May 14, 2009
The efficacy and tolerability of AST-120 (spherical carbon adsorbent) in active pouchitisBo Shen, Darrell S Pardi, Ana E Bennett, et al.
The American Journal of Gastroenterology|September 6, 2013
The relation between symptom improvement and gastric emptying in the treatment of diabetic and idiopathic gastroparesisPieter Janssen, M Scott Harris, Mike Jones, et al.
JHEP Reports : Innovation in Hepatology|October 20, 2025
Safety and efficacy of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease: A randomized, controlled clinical trialSarah K Browne, John J Suschak, Shaheen Tomah, et al.
Journal of Hepatology|July 13, 2024
Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled studyStephen A Harrison, Sarah K Browne, John J Suschak, et al.
Journal of Crohn'S & Colitis|January 30, 2016
AVX-470, an Orally Delivered Anti-Tumour Necrosis Factor Antibody for Treatment of Active Ulcerative Colitis: Results of a First-in-Human TrialM Scott Harris, Deborah Hartman, Brenda R Lemos, et al.
Journal of Crohn'S & Colitis|January 24, 2016
Effects of AVX-470, an Oral, Locally Acting Anti-Tumour Necrosis Factor Antibody, on Tissue Biomarkers in Patients with Active Ulcerative ColitisDeborah S Hartman, Daniel E Tracey, Brenda R Lemos, et al.
Intensive Care Medicine|May 8, 2019
A multicenter, randomized, double-blind study of ulimorelin and metoclopramide in the treatment of critically ill patients with enteral feeding intolerance: PROMOTE trialDaren K Heyland, Arthur R H van Zanten, Teodoro Grau-Carmona, et al.
Antibiotics (Basel, Switzerland)|August 29, 2024
Randomized, Double-Blind, Placebo-Controlled Study of Anti-Mycobacterial Therapy (RHB-104) in Active Crohn's DiseaseDavid Y Graham, Saleh A Naser, Thomas Borody, et al.
Lancet (London, England)|November 14, 2025
Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b studyMazen Noureddin, Stephen A Harrison, Rohit Loomba, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
The American Journal of Gastroenterology|July 9, 2020
Bimodal Release Ondansetron Improves Stool Consistency and Symptomatology in Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized, Double-Blind, TrialTerry F Plasse, Gary Barton, Evelyne Davidson, et al.
The American Journal of Gastroenterology|May 14, 2009
The efficacy and tolerability of AST-120 (spherical carbon adsorbent) in active pouchitisBo Shen, Darrell S Pardi, Ana E Bennett, et al.
The American Journal of Gastroenterology|September 6, 2013
The relation between symptom improvement and gastric emptying in the treatment of diabetic and idiopathic gastroparesisPieter Janssen, M Scott Harris, Mike Jones, et al.
JHEP Reports : Innovation in Hepatology|October 20, 2025
Safety and efficacy of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease: A randomized, controlled clinical trialSarah K Browne, John J Suschak, Shaheen Tomah, et al.
Journal of Hepatology|July 13, 2024
Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled studyStephen A Harrison, Sarah K Browne, John J Suschak, et al.
Journal of Crohn'S & Colitis|January 30, 2016
AVX-470, an Orally Delivered Anti-Tumour Necrosis Factor Antibody for Treatment of Active Ulcerative Colitis: Results of a First-in-Human TrialM Scott Harris, Deborah Hartman, Brenda R Lemos, et al.
Journal of Crohn'S & Colitis|January 24, 2016
Effects of AVX-470, an Oral, Locally Acting Anti-Tumour Necrosis Factor Antibody, on Tissue Biomarkers in Patients with Active Ulcerative ColitisDeborah S Hartman, Daniel E Tracey, Brenda R Lemos, et al.
Intensive Care Medicine|May 8, 2019
A multicenter, randomized, double-blind study of ulimorelin and metoclopramide in the treatment of critically ill patients with enteral feeding intolerance: PROMOTE trialDaren K Heyland, Arthur R H van Zanten, Teodoro Grau-Carmona, et al.
Antibiotics (Basel, Switzerland)|August 29, 2024
Randomized, Double-Blind, Placebo-Controlled Study of Anti-Mycobacterial Therapy (RHB-104) in Active Crohn's DiseaseDavid Y Graham, Saleh A Naser, Thomas Borody, et al.
Lancet (London, England)|November 14, 2025
Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b studyMazen Noureddin, Stephen A Harrison, Rohit Loomba, et al.
Pageof 3